These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1840297)

  • 21. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS; Morillo CA; Connolly SJ
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Left heart insufficiency following acute myocardial infarct].
    Baumgartner I; Turina J
    Schweiz Med Wochenschr; 1994 Jul; 124(26):1191-5. PubMed ID: 8047866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Modification of hemodynamics by angiotensin converting enzyme inhibitors in heart failure].
    Ertl G; Gaudron P; Eilles C
    Herz; 1990 Jun; 15(3):158-63. PubMed ID: 2198216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses.
    Dzau VJ; Creager MA
    Cardiol Clin; 1989 Feb; 7(1):119-30. PubMed ID: 2650868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The extent of regional wall motion abnormalities identifies patients at risk of extensive left ventricular remodeling: implications for the design of post myocardial infarction trials.
    Zanolla L; Marino P; Golia G; Anselmi M; Zardini P; Borghi C; Ambrosioni E
    G Ital Cardiol; 1999 Jan; 29(1):20-6. PubMed ID: 9987043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Issues concerning the use of angiotensin-converting enzyme inhibitors in the treatment of heart failure and myocardial infarction.
    Poole-Wilson PA
    Arch Mal Coeur Vaiss; 1994 Jun; 87 Spec No 2():35-8. PubMed ID: 7864720
    [No Abstract]   [Full Text] [Related]  

  • 31. Development and prevention of congestive heart failure following myocardial infarction.
    Pfeffer MA; Pfeffer JM; Lamas GA
    Circulation; 1993 May; 87(5 Suppl):IV120-5. PubMed ID: 8485827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of ventricular remodelling post myocardial infarction: timing and duration of therapy.
    Jugdutt BI
    Can J Cardiol; 1993; 9(1):103-14. PubMed ID: 8439824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current aspects of ACE inhibitor therapy from the cardiologic viewpoint].
    Klein W; Eber B; Gasser R; Stoschitzky K; Schumacher M; Fruhwald FM; Zweiker R
    Wien Med Wochenschr; 1996; 146(11):221-4. PubMed ID: 8928518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
    Schunkert H; Holmer SR; Riegger G
    Z Kardiol; 1993; 82 Suppl 4():1-6. PubMed ID: 8147057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment by angiotensin converting enzyme inhibitors after myocardial infarction. What did the clinical trials teach us?].
    Guéret P; Garot J; Barnier P
    Arch Mal Coeur Vaiss; 1996 Aug; 89 Spec No 3():33-8. PubMed ID: 8949316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasodilator therapy for congestive heart failure. Lessons from mortality trials.
    Groden DL
    Arch Intern Med; 1993 Feb; 153(4):445-54. PubMed ID: 8435024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition.
    Lamas GA; Pfeffer MA
    Am Heart J; 1991 Apr; 121(4 Pt 1):1194-202. PubMed ID: 1826184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction.
    LeJemtel TH; Hochman JS; Sonnenblick EH
    J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):47S-51S. PubMed ID: 7775715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction.
    Pfeffer JM; Fischer TA; Pfeffer MA
    Annu Rev Physiol; 1995; 57():805-26. PubMed ID: 7778884
    [No Abstract]   [Full Text] [Related]  

  • 40. [ACE inhibition: indications in mild heart failure and asymptomatic left ventricular dysfunction?].
    Riegger AJ
    Verh Dtsch Ges Inn Med; 1991; 97():562-6. PubMed ID: 1808946
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.